Is the All Ordinaries Index staying afloat?

Published 29-MAR-2019 11:56 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

One hot topic this week was Wesfarmers proposing a $1.5 billion takeover bid for rare earth miner Lynas Corporation (LYC).

The unsolicited cash offer to purchase the stock at $2.25 per share was made at a 44.7% premium on the share price. However, the Lynas board rejected the offer due to the conditional aspects of the proposal and the belief that the company can deliver better value for its shareholders.

On news of the takeover, Lynas shares jumped 38% rising to a high of $2.17 before closing slightly lower.

The troubled miner’s processing plant faces closure in September if the company cannot come to an agreement with the Malaysian Government about toxic waste removal from its operations. As a consequence, prior to the takeover announcement Lynas shares were down 45% from its high in May last year.


While the move by Wesfarmers is timely and in line with its objective to acquire businesses with unique characteristics that will deliver value to shareholders, there is no value in buying or holding Lynas right now unless you believe Wesfarmers will significantly up its bid, which may or may not happen any time soon.

In another big move, Challenger Limited (CGF) jumped 9% on news that it would receive extended funding for reinsurance-based products from Japanese Insurance group, MS&AD. The group also intends to acquire a position on the board and increase its 15 per cent stake in Challenger, which could lead to an acquisition down the track.

Shares in IPH Limited also rose around 4% this week, after the ACCC stated that it wouldn’t oppose the takeover of a smaller competitor, Xenith. Taking a look at the sectors, Communication Services and Materials were up around 1% this week, while Energy and Information Technology were down around 3.5%. Financials have continued to slide down around 2% at one stage before rising slightly. In the past month, we have seen the big 4 all fall, with ANZ hit the hardest down around 7%, with CBA down 4%. AMP also continued its fall, down around 11% for the month, reaching a new all-time-low of $2.07.

While the Financial sector rose after the royal commission report was released, with investor’s hopeful the run would continue, we are now starting to see the dust settle and the sector is not looking all that strong. Therefore, I still believe this sector should be avoided in the short term, and that investors wait until the second half of the year when the banks are likely to perform better.

So what do we expect in the market?
With all the bearish news around, the All Ordinaries Index is continuing to surprise me by remaining so resilient. It was down over 1.5% at one stage earlier in the week and investors were wondering if it was time to jump ship, but it clawed back much of the fall. In fact, the market has performed strongly this year given that it has traded higher for 11 out of the 13 weeks and for 9 of those 13 weeks it closed higher than it opened.

Once again, I don’t believe the market has fallen far enough in price, therefore, we may see it fall another 1 or 2 per, with the fall being very short term. That said, if it takes off from its current levels, it just means a larger fall is expected either late in the 3rd quarter or early in the 4th quarter of 2019.

Over all, the market is bullish and we should see some smooth sailing ahead

Dale Gillham is Chief Analyst at Wealth Within and international bestselling author of How to Beat the Managed Funds by 20%. He is also author of Accelerate Your Wealth—It’s Your Money, Your Choice, which is available in book stores and online at www.wealthwithin.com.au



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X